INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the fourth most frequent type of malignancy among females and the fifth most frequent type among males in China, accounting for 160,600 and 215,700 cases in 2015, respectively \[[@R1]\]. The CRC morbidity is shooting up in developing countries including China \[[@R1], [@R2]\]; nevertheless, CRC etiology remains unknown. Risk factors, such as advanced age, family history of CRC, benign adenomatous polyp, inflammatory bowel disease, drinking, smoking, being physically inactive, low intake of fruits and vegetables and high intake of dietary fat, may play important roles in the occurrence and the development of CRC \[[@R3]--[@R9]\]. Accumulating evidences indicated that besides environmental factors and individual lifestyle, some genetic factors might be related to CRC etiology.

Several studies have found association between circulating or dietary folate level and the risk of CRC \[[@R10]--[@R12]\]. A long induction period deserves close attention to the study of CRC because the course from normal cells of the rectum and colon, to microadenomas, to macroadenomas, and eventually to adenocarcinomas, experiences over a long duration, approximately 30-40 years \[[@R13]\]. The presence of the long induction period between reduced risk of CRC and adequate folate status is evident in both epidemiologic and molecular mechanistic studies \[[@R14]\]. The lower folate levels lead to an increasing rate of DNA hypomethylation and uracil misincorporation even in non-neoplastic, normal-appearing tissue of cases \[[@R14]\]. Folate is reduced to tetrahydrofolate (THF) to participate in one-carbon metabolism \[[@R15]\]. Folate metabolism is accommodated by several enzymes. Methylenetetrahydrofolate reductase (MTHFR) is the key enzyme \[[@R16]--[@R18]\]. MTHFR is involved in DNA methylation, repair and synthesis \[[@R19]\]. DNA strand break and repair, and impaired DNA methylation have been associated with folate deficiency and CRC.

*MTHFR* gene locates on 1p36.22. The gene encodes a 74.6-kDa protein containing 656 amino acids. MTHFR is also linked to purine synthesis; therefore, plays a vital role in DNA synthesis by the provision of essential nucleotides \[[@R18]\]. Single nucleotide polymorphisms (SNPs) of *MTHFR* are considered as a potential biomarker which may influence CRC risk. Therefore, we carried out this case-control study in a Chinese Han population to determine whether *MTHFR* tagging SNPs (rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A) were associated with the risk of CRC.

RESULTS {#s2}
=======

Demographic characteristics {#s2_1}
---------------------------

The frequency distributions of age, sex, smoking status and drinking habit information for the 387 patients with CRC (mean ± SD age, 60.21 ± 12.48 years) and 1,536 controls (mean ± SD age, 60.82± 8.85 years) are shown in Table [1](#T1){ref-type="table"}. The age and sex of the CRC patients and controls were well-matched. The differences of smoking status and drinking habit between CRC and non-cancer controls were not statistically significant (*P* ≥ 0.05) (Table [1](#T1){ref-type="table"}). Tumor grade was defined as high (well differentiated), medium (moderately differentiated); and low (poorly differentiated). Two experienced doctors independently assessed disease stage according to the AJCC criteria (2010). Finally, 196 cases with stage I/II and 191 with stage III/IV were included. Among the CRC patients, 218 were rectum cancer and 169 were colon cancer. And the primary information for *MTHFR* polymorphisms is summarized in Table [2](#T2){ref-type="table"}.

###### Distribution of selected demographic variables and risk factors in colorectal cancer cases and controls

  Variable                       Cases (n=387)    Controls (n=1,536)   *P*^a^                  
  ------------------------------ ---------------- -------------------- --------------- ------- -------
  Age (years)                    60.21 (±12.48)                        60.82 (±8.85)           0.272
  Age (years)                                                                                  0.502
   \< 61                         186              48.06                709             46.16   
   ≥ 61                          201              51.94                827             53.84   
  Sex                                                                                          0.213
   Male                          236              60.98                989             64.39   
   Female                        151              39.02                547             35.61   
  Smoking status                                                                               0.505
   Never                         270              69.77                1098            71.48   
   Ever                          117              30.23                438             28.52   
  Alcohol use                                                                                  0.058
   Never                         335              78.55                1381            89.91   
   Ever                          52               21.45                155             10.09   
  Site of tumor                                                                                
   Colon cancer                  169              43.67                                        
   Rectum cancer                 218              56.33                                        
  Degree of differentiation^b^                                                                 
   Low                           56               16.28                                        
   Medium                        261              75.87                                        
   High                          27               7.85                                         
  Lymph node status                                                                            
   Positive                      177              45.74                                        
   Negative                      210              54.26                                        
  TMN stage                                                                                    
   I+II                          196              50.65                                        
   III+IV                        191              49.35                                        

^a^Two-sided *χ*^2^ test and Student t test.

###### Primary information for *MTHFR* polymorphisms (rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A)

  Genotyped SNPs                              rs3753584 T\>C   rs9651118 T\>C   rs1801133 G\>A   rs4846048 A\>G   rs4845882 G\>A
  ------------------------------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Chromosome                                  1                1                1                1                1
  Function                                    NearGene-5       Intron           Missense         Intron           Intron
  Chr Pos (Genome Build 36.3)                 11787173         11784801         11778965         11768839         11765754
  MAF^a^ for Chinese in database              0.093            0.382            0.439            0.105            0.198
  MAF in our controls (n = 1,536)             0.109            0.379            0.356            0.096            0.209
  *P* value for HWE^b^ test in our controls   0.164            0.134            0.747            0.082            0.733
  Genotyping method                           SNPscan          SNPscan          SNPscan          SNPscan          SNPscan
  \% Genotyping value                         99.64%           99.64%           99.64%           99.64%           99.64%

^a^MAF: minor allele frequency;

^b^HWE: Hardy--Weinberg equilibrium.

Association of MTHFR rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A polymorphisms with CRC patients {#s2_2}
--------------------------------------------------------------------------------------------------------------------------------------

The genotypes of *MTHFR* rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A polymorphisms in CRC patients and non-cancer controls are summarized in Table [3](#T3){ref-type="table"}. The observed genotype frequencies for the five *MTHFR* tagging SNPs in control group were all in HWE (*P* = 0.134, 0.082, 0.733, 0.164 and 0.747 for *MTHFR* rs9651118 T\>C, rs4846048 A\>G, rs4845882 G\>A, rs3753584 T\>C and rs1801133 G\>A, respectively), which suggested good homogeneity within the present study participants. Four CRC patients (1.03%) and three controls (0.19%) could not be genotyped for poor DNA quantity and/or quality. Overall, we found no statistically significant difference in genotype distribution of *MTHFR* rs3753584 T\>C, rs9651118 T\>C and rs4846048 A\>G polymorphisms among CRC patients and controls (Table [4](#T4){ref-type="table"}).

###### The frequencies of *MTHFR* rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A polymorphisms in colorectal cancer patients and controls

  Genotype                 Colorectal cancer (n=387)   Colon cancer   (n=169)   Rectum cancer (n=218)         Controls   (n=1,536)   
  ------------------------ --------------------------- -------------- --------- ----------------------- ----- ---------- ----------- -------
  *MTHFR* rs3753584 T\>C                                                                                                             
  TT                       287                         74.93          131       78.44                   156   72.22      1211        79.00
  TC                       89                          23.24          31        18.56                   58    26.85      309         20.16
  CC                       7                           1.83           5         2.99                    2     0.93       13          0.85
  CT+CC                    96                          25.07          36        21.56                   60    27.78      322         21.00
  TT+CT                    376                         98.17          162       97.01                   214   99.07      1,520       99.15
  CC                       7                           1.83           5         2.99                    2     0.93       13          0.85
  C allele                 103                         13.45          41        12.28                   62    14.35      335         10.93
  *MTHFR* rs9651118 T\>C                                                                                                             
  TT                       131                         34.20          56        33.53                   75    34.72      578         37.70
  TC                       188                         49.09          79        47.31                   109   50.46      749         48.86
  CC                       64                          16.71          32        19.16                   32    14.81      206         13.44
  TC+CC                    252                         65.80          111       66.47                   141   65.28      955         62.30
  TT+TC                    319                         83.29          135       80.84                   184   85.19      1,327       86.56
  CC                       64                          16.71          32        19.16                   32    14.81      206         13.44
  C allele                 316                         41.25          143       42.81                   173   40.05      1,161       37.87
  *MTHFR* rs1801133 G\>A                                                                                                             
  GG                       177                         46.21          82        49.10                   95    43.98      639         41.68
  GA                       175                         45.69          73        43.71                   102   47.22      697         45.47
  AA                       31                          8.09           12        7.19                    19    8.80       197         12.85
  GA + AA                  206                         53.79          85        50.90                   121   56.02      894         58.32
  GG+ GA                   352                         91.91          155       92.81                   197   91.20      1,336       87.15
  AA                       31                          8.09           12        7.19                    19    8.80       197         12.85
  A allele                 237                         30.94          97        29.04                   140   32.41      1,091       35.58
  *MTHFR* rs4846048 A\>G                                                                                                             
  AA                       308                         80.42          136       81.44                   172   79.63      1259        82.13
  AG                       70                          18.28          30        17.96                   40    18.52      254         16.57
  GG                       5                           1.31           1         0.60                    4     1.85       20          1.30
  AG+GG                    75                          19.58          31        18.56                   44    20.37      274         17.87
  AA+AG                    378                         98.69          166       99.40                   212   98.15      1,513       98.70
  GG                       5                           1.31           1         0.60                    4     1.85       20          1.30
  G allele                 80                          10.44          32        9.58                    48    11.11      294         9.59
  *MTHFR* rs4845882 G\>A                                                                                                             
  GG                       228                         59.53          103       61.68                   125   57.87      956         62.36
  GA                       129                         33.68          54        32.34                   75    34.72      512         33.40
  AA                       26                          6.79           10        5.99                    16    7.41       65          4.24
  GA+AA                    155                         40.47          64        38.32                   91    42.13      577         37.64
  GG+GA                    357                         93.21          157       94.01                   200   92.59      1,468       95.76
  AA                       26                          6.79           10        5.99                    16    7.41       65          4.24
  A allele                 181                         23.63          74        22.16                   107   24.77      642         20.94

###### Overall and stratified analyses of *MTHFR* rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A polymorphisms with colorectal cancer

  Genotype                 Overall colorectal cancer cases (n=387)   Colon cancer (n=169)   Rectum cancer (n=218)                                                                                                                                               
  ------------------------ ----------------------------------------- ---------------------- ----------------------- ----------- ---------------------- ----------- ---------------------- ----------- ---------------------- ----------- ---------------------- -----------
  *MTHFR* rs3753584 T\>C                                                                                                                                                                                                                                        
  Additive model           1.20 (0.92-1.57)                          0.180                  1.20 (0.92-1.58)        0.178       0.92(0.61-1.38)        0.674       0.92(0.61-1.38)        0.679       **1.44(1.04-2.00)**    **0.028**   **1.44(1.04-2.00)**    **0.030**
  Homozygote model         2.25 (0.89-5.68)                          0.087                  2.34 (0.92-5.93)        0.074       **3.51(1.23-10.01)**   **0.019**   **3.63(1.27-10.38)**   **0.016**   1.18 (0.26-5.29)       0.827       1.20 (0.27-5.38)       0.815
  Dominant model           1.26 (0.97-1.63)                          0.086                  1.26 (0.97-1.64)        0.081       1.03(0.70-1.53)        0.867       1.04(0.70-1.53)        0.852       **1.45 (1.05-2.00)**   **0.025**   **1.44 (1.04-2.00)**   **0.026**
  Recessive model          2.18(0.86-5.49)                           0.100                  2.26 (0.89-5.73)        0.085       **3.61(1.27-10.26)**   **0.016**   **3.74(1.31-10.64)**   **0.014**   1.09(0.25-4.88)        0.908       1.11 (0.25-4.97)       0.894
  *MTHFR* rs9651118 T\>C                                                                                                                                                                                                                                        
  additive model           1.08(0.84-1.38)                           0.539                  1.08(0.85-1.39)         0.528       1.06(0.74-1.51)        0.762       1.06 (0.75-1.52)       0.734       1.10 (0.80-1.50)       0.556       1.10 (0.80-1.50)       0.552
  homozygote model         1.34 (0.95-1.87)                          0.091                  1.36 (0.97-1.90)        0.077       1.56(0.98-2.47)        0.060       1.56 (0.99-2.48)       0.057       1.17 (0.75-1.82)       0.481       1.22 (0.78-1.90)       0.390
  Dominant model           1.16(0.92-1.47)                           0.205                  1.17(0.93-1.48)         0.190       1.20(0.86-1.68)        0.290       1.21 (0.86-1.69)       0.275       1.14 (0.84-1.53)       0.397       1.15 (0.85-1.55)       0.368
  Recessive model          1.29 (0.95-1.76)                          0.100                  1.31(0.96-1.78)         0.084       **1.53(1.01-2.31)**    **0.044**   **1.53(1.01-2.31)**    **0.044**   1.12(0.75-1.68)        0.581       1.16 (0.77-1.74)       0.471
  *MTHFR* rs1801133 G\>A                                                                                                                                                                                                                                        
  additive model           0.89 (0.71-1.13)                          0.331                  0.89(0.70-1.12)         0.322       0.80(0.58-1.12)        0.188       0.80(0.57-1.11)        0.183       0.97(0.72-1.31)        0.834       0.97(0.72-1.30)        0.817
  homozygote model         **0.56 (0.37-0.84)**                      **0.006**              **0.56 (0.37-0.84)**    **0.005**   **0.47(0.25-0.87)**    **0.017**   **0.46 (0.25-0.86)**   **0.015**   0.64 (0.38-1.07)       0.089       0.64 (0.38-1.07)       0.090
  Dominant model           0.83 (0.66-1.04)                          0.109                  0.83 (0.66-1.04)        0.106       0.74(0.54-1.02)        0.066       0.74(0.54-1.02)        0.063       0.91(0.68-1.21)        0.522       0.91(0.68-1.21)        0.512
  Recessive model          **0.60 (0.40-0.89)**                      **0.011**              **0.60 (0.40-0.89)**    **0.011**   **0.53 (0.29-0.96)**   **0.037**   **0.52(0.28-0.95)**    **0.035**   0.65 (0.40-1.07)       0.092       0.66 (0.40-1.08)       0.095
  *MTHFR* rs4846048 A\>G                                                                                                                                                                                                                                        
  additive model           1.12(0.83-1.49)                           0.466                  1.11(0.83-1.49)         0.474       1.08(0.71-1.64)        0.717       1.08 (0.71-1.63)       0.735       1.14 (0.79-1.65)       0.480       1.14(0.79-1.66)        0.482
  homozygote model         1.01 (0.38-2.72)                          0.982                  0.98 (0.36-2.63)        0.961       0.46(0.06-3.43)        0.447       0.46 (0.06-3.48)       0.454       1.45 (0.49-4.30)       0.501       1.36 (0.45-4.07)       0.583
  Dominant model           1.12(0.84-1.49)                           0.439                  1.11(0.84-1.48)         0.457       1.05(0.69-1.58)        0.826       1.04 (0.69-1.58)       0.839       1.18 (0.82-1.68)       0.373       1.17 (0.82-1.67)       0.393
  Recessive model          1.00(0.37-2.68)                           1.000                  0.96(0.36-2.59)         0.938       0.46(0.06-3.42)        0.445       0.46(0.06-3.45)        0.450       1.43(0.48-4.22)        0.519       1.33 (0.45-3.98)       0.609
  *MTHFR* rs4845882 G\>A                                                                                                                                                                                                                                        
  additive model           1.04 (0.82-1.33)                          0.741                  1.05 (0.82-1.33)        0.720       0.96 (0.68-1.36)       0.832       0.97 (0.68-1.36)       0.843       1.11(0.82-1.50)        0.517       1.11(0.82-1.51)        0.508
  homozygote model         **1.65 (1.03-2.66)**                      **0.039**              **1.64 (1.02-2.65)**    **0.043**   1.41(0.70-2.82)        0.338       1.42 (0.71-2.85)       0.326       **1.86(1.04-3.31)**    **0.035**   1.79 (1.00-3.20)       0.050
  Dominant model           1.13 (0.90-1.42)                          0.308                  1.13 (0.90-1.42)        0.300       1.03(0.74-1.43)        0.862       1.03(0.74-1.44)        0.845       1.21 (0.90-1.61)       0.204       1.20 (0.90-1.61)       0.211
  Recessive model          **1.65(1.03-2.63)**                       **0.038**              **1.63 (1.01-2.60)**    **0.044**   1.44 (0.73-2.86)       0.299       1.45 (0.73-2.88)       0.290       **1.81(1.03-3.18)**    **0.041**   1.73(0.98-3.07)        0.059

^a^Adjusted for age, sex, smoking status and alcohol use in a logistic regression model.

When compared with *MTHFR* rs1801133 GG genotype, *MTHFR* rs1801133 AA genotype was associated with a decreased risk of CRC (crude OR = 0.56, 95% CI: 0.37--0.84, *P* = 0.006). When compared with *MTHFR* rs1801133 GG/GA genotype, *MTHFR* rs1801133 AA genotype was also associated with a decreased risk of CRC (crude OR = 0.60, 95% CI: 0.40--0.89, *P* = 0.011). Adjustment for multiple factors (age, sex, smoking and drinking), the results were not essentially changed (AA vs. GG: adjusted OR = 0.56, 95% CI: 0.37--0.84, *P* = 0.005; AA vs. GG/GA: OR = 0.60, 95% CI: 0.40--0.89, *P* = 0.011; Table [4](#T4){ref-type="table"}).

When compared with *MTHFR* rs4845882 GG genotype, a *MTHFR* rs4845882 AA genotype increased the risk of CRC (crude OR = 1.65, 95% CI: 1.03--2.66, *P* = 0.039). When compared with *MTHFR* rs4845882 GG/GA genotype, *MTHFR* rs4845882 AA genotype was associated with an increased risk of CRC (crude OR = 1.65, 95% CI: 1.03--2.63, *P* = 0.038). Adjustment for multiple factors (age, sex, smoking and drinking), the results were not essentially changed (AA vs. GG: adjusted OR =1.64 95% CI: 1.02--2.65, *P* = 0.043; AA vs. GG/GA: OR = 1.63, 95% CI: 1.01--2.60, *P* = 0.044; Table [4](#T4){ref-type="table"}).

Association of MTHFR rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A polymorphisms with CRC in a stratification group {#s2_3}
-------------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether the effect of *MTHFR* polymorphisms was influenced by CRC region, we performed a stratified analysis. For *MTHFR* rs3753584 T\>C polymorphism, we found this polymorphism was associated with an increased risk of rectum cancer (CC+TC *vs*. TT: adjusted OR = 1.44, 95% CI = 1.04--2.00, *P* = 0.026; TC *vs*. TT: adjusted OR = 1.44, 95% CI = 1.04--2.00, *P* = 0.030) and of colon cancer (CC *vs*. TT+TC: adjusted OR = 3.74, 95% CI = 1.31--10.64, *P* = 0.014; CC *vs*. TT: adjusted OR = 3.63, 95% CI = 1.27--10.38, *P* = 0.016). For *MTHFR* rs9651118 T\>C polymorphism, we found *MTHFR* rs9651118 CC genotypes might be associated with an increased risk of colon cancer (CC *vs*. TT+TC: adjusted OR = 1.53, 95% CI = 1.01--2.31, *P* = 0.044). However, we found *MTHFR* rs1801133 G\>A polymorphism was associated with a decreased risk of colon cancer (AA *vs*. GG+GA: adjusted OR = 0.52, 95% CI = 0.28--0.95, *P* = 0.035; AA *vs*. GG: adjusted OR = 0.46, 95% CI = 0.25--0.86, *P* = 0.015). Other comparisons are presented in Table [4](#T4){ref-type="table"}.

The power of the present study (α= 0.05) {#s2_4}
----------------------------------------

For *MTHFR* rs3753584 T\>C, the power value was 0.634 in homozygote model and 0.651 in recessive model among colon cancer group, and 0.586 in homozygote model and 0.614 in recessive model among rectum cancer group. In addition, for *MTHFR* rs9651118 T\>C, the power value was 0.527 in recessive model among colon cancer group. Moreover, for *MTHFR* rs1801133 G\>A, the power value was 0.815 in homozygote model and 0.748 in recessive model among overall CRC group, and 0.705 in homozygote model and 0.565 in recessive model among colon cancer group. For *MTHFR* rs4845882 G\>A, the power value was 0.537 in homozygote model and 0.553 in recessive model among overall CRC group, and 0.494 in homozygote model and 0.540 in recessive model among rectum cancer group as well.

DISCUSSION {#s3}
==========

Recently, CRC incidence and related mortality are increasing rapidly worldwide. The individual\'s susceptibility to CRC may be influenced by some environmental exposure and genetic factors. Recently, many case-control studies have been directed towards the association between *MTHFR* polymorphisms and CRC risk. However, the sample size of most studies was relatively small. Here, we attempt to assess the association between *MTHFR* tagging SNPs (rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A) and susceptibility of CRC. Our results indicated several *MTHFR* tagging polymorphisms could affect the risk of CRC.

*MTHFR* rs1801133 G\>A polymorphism leads to an amino acid transformation (alanine→valine at 226 position of MTHFR protein). The role of MTHFR enzyme is remethylation of homocysteine to methionine. Polymorphisms in MTHFR gene are corrected with the deficiency of MTHFR enzyme activity. Compared with rs1801133 GG homozygote, MTHFR rs1801133 AA homozygote decreases 70% of the enzyme activity and MTHFR rs1801133 GA heterozygote loss 35% of enzymatic function. This transformation may increase the plasma homocysteine (Hcy) concentration and decreases the plasma folic acid concentration \[[@R26]\]. Recently, several meta-analyses indicated that *MTHFR* rs1801133 G\>A polymorphism decreased the risk of CRC in Asians \[[@R27], [@R28]\]. *MTHFR* rs1801133 G\>A polymorphism locates on the NH2-terminal catalytic domain. In addition, *MTHFR* rs1801133 G\>A polymorphism increases the availability of 5, 10-methylenetetrahydrofolate for DNA synthesis \[[@R29], [@R30]\], which may partially explain the protective factor of CRC. In combination with this case-control study, our results evidence that G→A mutation in *MTHFR* rs1801133 increases the availability of 5, 10-methylenetetrahydrofolate for DNA synthesis; thus, this SNP may be a protective factor of CRC.

To the best of our knowledge, it was the first epidemiological study to explore the relationship of *MTHFR* rs4845882 G\>A polymorphism with CRC risk. *MTHFR* rs4845882 G\>A is linkage disequilibrium (LD) with rs1801131 (1298 A\>C). Several meta-analyses suggested that *MTHFR* rs1801131 A\>C polymorphism affected risk of CRC in Asians \[[@R31], [@R32]\]. In the present study, we found *MTHFR* rs4845882 G\>A polymorphism may be associated with the development of CRC. Since *MTHFR* rs4845882 G\>A and rs1801131 A\>C are in strong LD (*r^2^* = 0.935, <http://gvs.gs.washington.edu/GVS147/LDpairwiseR2.jsp?GET_TAYLORGRAM=1491876387794>), the function of rs4845882 G\>A may be affected by rs1801131 A\>C.

A study reported that CC genotype of *MTHFR* rs9651118 conferred a reduced risk of breast cancer compared to TT genotype in a Chinese population \[[@R33]\]. Swartz *et al*. found *MTHFR* rs9651118 T\>C polymorphism may be correlated with the decreased risk of lung cancer in Caucasians \[[@R34]\]. In our previous study, we found there was null association between *MTHFR* rs9651118 T\>C polymorphism and esophageal squamous cell carcinoma in a Chinese Han population \[[@R21]\]. However, in this study, we found that rs9651118 CC genotype was relevant to increased risk of colon cancer. Rs9651118 T\>C polymorphism is located on the intron of *MTHFR* gene. The function of this polymorphism is not well known. It was reported that *MTHFR* rs9651118 TT genotype elevated the level of Hcy compared with CC genotype \[[@R35]\]. In the future, more functional studies are required to identify the real biological effect of *MTHFR* rs9651118 T\>C polymorphism on the etiology of CRC.

In a subgroup analysis by the region of CRC, *MTHFR* rs3753584 T\>C polymorphism was associated with the risk of colon and rectum cancer. Although the function of *MTHFR* rs3753584 T\>C polymorphism was not identified, a significantly increased risk of lung cancer was found for the variant allele carriers of this polymorphism, compared with individuals with wild homozygote \[[@R36]\]. In this study, we also found that C allele of *MTHFR* rs3753584 was probably correlated with an increased risk of colon and rectum cancer, which was consistent with the findings of those previous study.

Like all case-control studies, this study has some limitations. First, demographic variables and risk factor information only focused on age, sex, smoking and alcohol consumption. And other lifestyles were not collected, which might increase the possibility of confounding from environmental risk factors. Second, the source of non-cancer controls was hospital-based; which might not well represent the whole Chinese population. Third, in a stratified analysis by the region of CRC, the relatively small sample size may decrease the power of the results. Finally, these findings should be interpreted with very caution because the participants were only enrolled from Chinese Han population. Thus, the results may not permit extrapolation to other ethnicities.

In summary, the tagging polymorphisms in *MTHFR* gene (rs3753584 T\>C, rs9651118 T\>C and rs4845882 G\>A) are associated with an increased risk of CRC. However, *MTHFR* rs1801133 G\>A polymorphism confers a decreased risk to CRC. Our findings suggest that further validation studies are needed.

MATERIALS AND METHODS {#s4}
=====================

Study population and patient selection {#s4_1}
--------------------------------------

The study population consisted of 387 sporadic, consecutive CRC patients from the Department of General Surgery, Fujian Medical University Union Hospital (Fuzhou, China) between October 2014 and May 2016. Histological report confirmed the diagnosis of CRC. Non-cancer controls (n = 1,536) were randomly recruited from the Fujian Medical University Union Hospital (Fuzhou, China) and the Affiliated People\'s Hospital of Jiangsu University (Zhenjiang, China) between October 2014 and November 2016. The CRC patients and controls were matched for age, sex and residential area (Eastern China). Every participant was informed the aim of the present study and signed an informed consent. The protocol of the study was obtained by the institutional ethics committee of Fujian Medical University and Jiangsu University. Additionally, in this case-control study, we conformed to the principles of Declaration of Helsinki.

Data collection {#s4_2}
---------------

Every participant was personally questioned and answered a questionnaire regarding age, sex, the status of cigarette smoking, and alcohol consumption. Participants who drink more than thrice/week for \>6 months and smoke at least one cigarette/day over 1 year were considered positive. Clinical characteristics, such as pathological stage and tumor site, were obtained from the medical records (Table [1](#T1){ref-type="table"}).

Selection of tagging SNPs {#s4_3}
-------------------------

The tagging SNPs of *MTHFR* gene \[30.4 Kbp spanning from 11780730 to 11811103 in chromosome 1 (upstream and downstream of the gene extending 5000 bases, respectively)\] were analyzed and selected from the data of Chinese Han individuals in Beijing (CHB) via the HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/index.html.en>) \[[@R20]\]. The detailed process and criterion were described previously \[[@R21]\]. The information of selected *MTHFR* tagging SNPs is presented in Table [2](#T2){ref-type="table"}.

DNA extraction and genotyping {#s4_4}
-----------------------------

Ethylenediamine tetraacetic acid-anticoagulated intravenous blood was donated by every participant. Using the Promega DNA Blood Mini Kit (Promega, Madison, USA), genomic DNA was extracted from peripheral lymphocytes by the standard experimental protocol.

A custom-by-design 48-Plex SNPscan Kit (Genesky Biotechnologies Inc., Shanghai, China), double ligation and multiplex fluorescence PCR \[[@R22]\], was performed to identify the genotypes of *MTHFR* rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A polymorphisms as described in previous studies \[[@R23], [@R24]\]. A total of 77 samples were randomly selected and were tested again for quality control. Based on 4% of duplicated samples in this study, the accordance rates were 100%.

Statistical analysis {#s4_5}
--------------------

We used SAS statistical software, version 9.4 (SAS Institute, Cary, NC) for data analysis and a *P* \< 0.05 (two--tailed) was considered to be a statistical significance. The quantitative variables were expressed as means ± standard deviation (SD). Student\'s t-test was harnessed to evaluate the difference of age between CRC patients and controls. Additionally, we used *χ^2^* test to examine the differences in age, sex, smoking status, alcohol consumption and the frequencies of genotype between patients with CRC and controls. The Hardy-Weinberg equilibrium (HWE) equation was used to assess whether the proportion of *MTHFR* tagging SNPs genotypes obtained was in accordance with the expected value. An online calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) was harnessed to calculate the *P* value of HWE \[[@R25]\]. The relationship of *MTHFR* rs3753584 T\>C, rs9651118 T\>C, rs1801133 G\>A, rs4846048 A\>G and rs4845882 G\>A genotypes with CRC risk was estimated by crude/adjusted odds ratios (ORs) and 95% confidence intervals (CIs). The power of the present study (α= 0.05) was evaluated by the Power and Sample Size Calculator (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>).
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